To include your compound in the COVID-19 Resource Center, submit it here.

Parathyroid hormone: Completed Phase II enrollment

Unigene completed enrollment of about 93 postmenopausal women with osteoporosis in the double-blind, placebo-controlled Phase II trial comparing its once-daily

Read the full 200 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE